Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

710.10INR
30 Jul 2015
Change (% chg)

Rs32.45 (+4.79%)
Prev Close
Rs677.65
Open
Rs682.20
Day's High
Rs713.50
Day's Low
Rs682.20
Volume
236,173
Avg. Vol
159,840
52-wk High
Rs752.45
52-wk Low
Rs430.35

CIPL.BO

Chart for CIPL.BO

About

Cipla Limited (Cipla) is an India-based global pharmaceutical company. The Company’s portfolio includes approximately 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2012/13 was approximately 1.5 billion USD. The Company’s research and development focus on developing products... (more)

Overall

Beta: 0.47
Market Cap(Mil.): Rs545,749.88
Shares Outstanding(Mil.): 803.10
Dividend: 2.00
Yield (%): 0.29

Financials

  CIPL.BO Industry Sector
P/E (TTM): 46.40 36.70 40.26
EPS (TTM): 14.64 -- --
ROI: 11.18 16.44 15.71
ROE: 11.33 17.21 16.73
Search Stocks

Sensex extends gains for second session

MUMBAI - The BSE Sensex and Nifty rose on Thursday, posting their second consecutive session of gains, backed by strong earnings of Bank of Baroda and Dr Reddy's Laboratories while continued optimism over the proposed national tax bill also helped.

6:36am EDT

India's Cipla expects to double respiratory drug sales by 2020

MUMBAI - Indian generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

Interview - Cipla expects to double respiratory drug sales by 2020

MUMBAI - Generic drugmaker Cipla expects sales from its respiratory portfolio to more than double by 2020 and remains on track to launch its potentially lucrative inhaler in Britain, its chief executive said.

17 Jun 2015

India's Cipla to sharpen focus on emerging markets in growth push

MUMBAI, June 17 - Cipla Ltd, India's fourth-largest drugmaker by sales, is planning to enter Latin America and Eastern Europe to tap into growing demand for generic drugs in emerging markets, Chief Executive Subhanu Saxena said.

17 Jun 2015

India's Lupin, Cipla bid for UCB's US generic drugs portfolio - Bloomberg

MUMBAI, June 1 - Indian generic drugmakers Lupin Ltd and Cipla Ltd are among the companies bidding for top Belgian drugmaker UCB SA's U.S. generic drugs business, Bloomberg reported on Monday, citing unnamed people with knowledge of the matter.

01 Jun 2015

Germany's Boehringer loses India patent on lung drug to Cipla

MUMBAI, March 10 - India has revoked a patent on German pharmaceutical company Boehringer Ingelheim's lung drug Spiriva and ruled in favour of domestic drugmaker Cipla Ltd , in the latest setback for a multinational drugmaker operating in India.

10 Mar 2015

BRIEF-India's Cipla agrees to buy 60 pct stake in Jay Precision for $15 mln

* Says agrees to buy 60 percent stake in Jay Precision Pharmaceuticals Pvt Ltd for 960 million rupees ($15.44 million) in cash

12 Feb 2015

India's Cipla Q3 net profit up 15.5 pct

MUMBAI, Feb 12 - Cipla Ltd, India's fourth-largest drugmaker by sales, on Thursday reported a 15.5 percent rise in its third-quarter profit, slightly lagging analysts' estimates.

12 Feb 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Motilal Oswal Securities Ltd.
$115.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks